Armata Pharmctcl Financials

No, Armata Pharmctcl (ARMP) reported a net income of -$18.9M in fiscal year 2024.

Armata Pharmctcl (ARMP) reported diluted earnings per share of $-0.89 for fiscal year 2024. This represents a 53.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Armata Pharmctcl (ARMP) had EBITDA of -$41.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Armata Pharmctcl (ARMP) generated -$39.4M in free cash flow during fiscal year 2024. This represents a 29.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Armata Pharmctcl (ARMP) generated -$37.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Armata Pharmctcl (ARMP) had $86.4M in total assets as of fiscal year 2024, including both current and long-term assets.

Armata Pharmctcl (ARMP) invested $1.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Armata Pharmctcl (ARMP) invested $34.4M in research and development during fiscal year 2024.

Armata Pharmctcl (ARMP) had 36M shares outstanding as of fiscal year 2024.

Armata Pharmctcl (ARMP) had a current ratio of 0.23 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Armata Pharmctcl (ARMP) had a debt-to-equity ratio of -2.80 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Armata Pharmctcl (ARMP) had a return on assets of -21.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Armata Pharmctcl (ARMP) had $9.3M in cash against an annual operating cash burn of $37.6M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Armata Pharmctcl (ARMP) has negative shareholder equity of -$48.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Armata Pharmctcl (ARMP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Armata Pharmctcl (ARMP) has an earnings quality ratio of 1.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.